default author photo

Arndt Vogel

Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology

Carl-Neuberg-Str. 1

Hannover, 30625

Germany

SCHOLARLY PAPERS

9

DOWNLOADS

593

TOTAL CITATIONS

4

Scholarly Papers (9)

1.

Pemigatinib for Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma

Number of pages: 40 Posted: 02 Dec 2019
Memorial Sloan Kettering Cancer Center - Department of Medicine, University of Michigan at Ann Arbor, University of Paris-Saclay - Gustave Roussy Cancer Center, Providence Cancer Center, University of Verona, University of Kansas - Cancer Center, Baylor University - Charles A. Sammons Cancer Center, Mayo Clinic Hospital - Phoenix, Morristown Memorial Hospital, Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center, Seoul National University - Department of Internal Medicine, Temple University - Fox Chase Cancer Center, University of Chicago - Pritzker School of Medicine, KU Leuven, Incyte Corporation, Incyte Corporation, Incyte Corporation, Incyte Corporation and Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology
Downloads 137 (534,155)
Citation 1

Abstract:

Loading...

FGR2, fusion; rearrangement; pemigatinib; INCB054828; intrahepatic cholangiocarcinoma; cholangiocarcinoma; biliary tract cancer

2.

The GALAD Score as Potential Screening Test for Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis: An International Multicenter Study

Number of pages: 24 Posted: 15 May 2019
University of Duisburg-Essen - University Hospital Essen, University Hospital Magdeburg - Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg - Department of Gastroenterology, Hepatology and Infectious Diseases, University of Duisburg-Essen - University Hospital Essen, University of Duisburg-Essen - University Hospital Essen, University of Duisburg-Essen - University Hospital Essen, University of Duisburg-Essen - University Hospital Essen, University Hospital Würzburg, University of Leipzig - University Hospital Leipzig, University of Leipzig - University Hospital Leipzig, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Johannes Gutenberg University Mainz - University Medical Center, Johannes Gutenberg University Mainz - University Medical Center, Johannes Gutenberg University Mainz - University Medical Center, University of Hamburg - Department of Medicine, University of Hamburg - Department of Medicine, University of Hamburg - Department of Medicine, University of Freiburg - Faculty of Medicine, University of Freiburg - Faculty of Medicine, University Hospital Magdeburg - Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg - Department of Gastroenterology, Hepatology and Infectious Diseases, Heidelberg University - University Hospital Heidelberg, Kitasato University - Department of Gastroenterology, Ogaki Municipal Hospital, Gifu Kyoritsu University, University of Liverpool, University of Duisburg-Essen - University Hospital Essen, University of Marburg, University of Duisburg-Essen - University Hospital Essen, University of Liverpool and University Hospital Magdeburg - Department of Gastroenterology, Hepatology and Infectious Diseases
Downloads 80 (803,225)

Abstract:

Loading...

NASH, NAFLD, HCC, diagnostic serological tests, AFP, AFP-L3, DCP, GALAD

3.

Reproducible Safety and Efficacy of Atezolizumab Plus Bevacizumab for HCC in Clinical Practice: Results of the AB-Real Study

Number of pages: 19 Posted: 09 Jul 2022
Imperial College London - Hammersmith Hospital, CHA University - CHA Bundang Medical Center, Imperial College London - Hammersmith Hospital, Kindai University, Mount Sinai Health System - Division of Hematology/ Oncology, Mount Sinai Health System - Precision Immunology Institute, Mount Sinai Health System - Division of Hematology/ Oncology, University of Kansas - Cancer Center, University of Kansas - Cancer Center, IRCCS Humanitas Research Hospital, IRCCS Humanitas Research Hospital, IRCCS Humanitas Research Hospital, University of Vienna, University of Vienna, Medical University of Vienna - Vienna Hepatic Hemodynamic Laboratory, Royal Marsden NHS Foundation Trust, National Yang Ming University - Taipei Veterans General Hospital, University of Texas at Dallas - Southwestern Medical Center, University of Oklahoma - Stephenson Cancer Center, University of Pisa, University of Pisa, University of Pisa, University of Freiburg - Faculty of Medicine, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University of Hamburg - University Medical Center Hamburg-Eppendorf, University Medical Center Mainz, Kindai University - Department of Gastroenterology and Hepatology, IRCCS Humanitas Research Hospital, University of Texas at Dallas - Division of Digestive and Liver Diseases, Imperial College London, Imperial College London - Hammersmith Hospital, Roche, CHA University - CHA Bundang Medical Center and Imperial College London
Downloads 71 (867,774)

Abstract:

Loading...

Advanced HCC, systemic treatment, first line, atezolizumab, bevacizumab

4.

Presentation, Management and Outcome of Cholangiocarcinoma in Europe: Results From Real-World Patient Registry

Number of pages: 75 Posted: 25 May 2021
Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, The Christie NHS Foundation Trust - Department of Medical Oncology, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Erasmus MC University Medical Center - Department of Surgery, University of Regensburg - Institute of Pathology, University of Amsterdam - Cancer Center Amsterdam, Department of Medical Oncology, Hospital Universitario 12 de Octubre - Department of Medical Oncology, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Humanitas University - Division of Internal Medicine and Hepatology, University of Padua - DMM Department of Molecular Medicine, Universidad de Navarra - Clinica Universidad de Navarra and Program in Solid Tumors (CIMA), Sorbonne Université - Department of Hepatobiliary and Liver Transplantation Surgery, Sapienza University of Rome - Translational and Precision Medicine, University of Glasgow - Institute of Cancer Sciences, University of Sassari - Department of Medical, Surgical and Experimental Sciences, University of Glasgow - Institute of Cancer Sciences, Carlos III National Institute of Health - Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Klinik Favoriten - Department for Surgery, Università Politecnica delle Marche - Department of Gastroenterology, Medical University of Warsaw - Department of General, Transplant and Liver Surgery, Oslo University Hospital Rikshospitalet - Norwegian PSC Research Center, Department of Transplantation Medicine, Lithuanian University of Health Sciences - Department of Gastroenterology and Institute for Digestive Research, University of Medicine and Pharmacy - Institute for Gastroenterology and Hepatology, 3rd Medical Department, Saarland University - Department of Medicine II, Teaching Hospital No. 1 - of Gastroenterology and Hepatology with General Medicine Unit, Grigore T. Popa University of Medicine and Pharmacy - Department of Morpho-Functional Sciences I, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Erasmus MC University Medical Center - Department of Surgery, University of Regensburg - Institute of Pathology, University of Amsterdam - Department of Surgery, Hospital Universitario 12 de Octubre - Department of Medical Oncology, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, University of Regensburg - Institute of Pathology, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Sapienza University of Rome - Department of Movement, Human and Health Sciences, University of Copenhagen - Biotech Research and Innovation Centre, University of Salamanca - Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Sapienza University of Rome - Translational and Precision Medicine, Biodonostia Health Research Institute - Department of Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III” (ISCIII) - National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, The Christie NHS Foundation Trust - Department of Medical Oncology, Erasmus University Rotterdam (EUR) - Department of Surgery and University of the Basque Country - Department of Liver and Gastrointestinal Diseases
Downloads 70 (875,328)

Abstract:

Loading...

cholangiocarcinoma; International Classification of Diseases 11th edition (ICD-11); subtypes; diagnosis; risk factors; treatment; prognosis

5.

Overall Survival and Objective Response in Advanced Unresectable Hepatocellular Carcinoma: A Subanalysis of the REFLECT Study

Number of pages: 35 Posted: 08 Feb 2020
Kindai University - Department of Gastroenterology and Hepatology, University of California, Los Angeles (UCLA) - David Geffen School of Medicine, Nanjing Bayi Hospital, Yonsei University - Severance Hospital, Toranomon Hospital - Department of Hepatology, National Taiwan University - Department of Internal Medicine, University of Bologna, Kindai University - Faculty of Medicine, Hiroshima University - Hiroshima University Hospital, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Hospital Marqués de Valdecilla, Comprehensive Cancer Center Eugène Marquis, Fudan University - Shanghai Cancer Center (FUSCC), Azienda Ospedaliera G. Rummo, National Cancer Center, Korea, Clatterbridge Cancer Centre, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc., Eisai, Inc. - Eisai, Inc. - United States and University of Miami - Miller School of Medicine
Downloads 69 (883,195)
Citation 1

Abstract:

Loading...

landmark analysis; lenvatinib; mRECIST; response status; surrogate endpoint

6.

Nal-Iri and 5-FU/LV Compared to 5-FU/LV in Patients with Cholangio- and Gallbladder Carcinoma Previously Treated with Gemcitabine-Based Therapies: The AIO NALIRICC Trial

Number of pages: 24 Posted: 23 Feb 2024
Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Technische Universität München (TUM), University of Hamburg - University Medical Center Hamburg-Eppendorf, Dresden University of Technology - University Clinic Carl Gustav Carus, Charité - Universitätsmedizin Berlin - Berlin Institute of Health, Oncodoc GmbH, HOPE—Practice for Oncology, HELIOS Hospital, Ludwig Maximilian University of Munich (LMU), Leopoldina Hospital Schweinfurt, Heidelberg University, HOPE—Practice for Oncology, HOPE—Practice for Oncology, HOPE—Practice for Oncology, Department of Hematology, Oncology and Gastroenterology, Maria Hilf Kliniken, University of Greifswald - University Hospital Greifswald, Institut für Klinisch-Onkologische Forschung Krankenhaus Nordwest Frankfurt/Main and Schleswig-Holstein University - University Medical Center
Downloads 55 (1,010,164)

Abstract:

Loading...

Cholangiocarcinoma, chemotherapy, Irinotecan, second line

7.

Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy

Number of pages: 31 Posted: 03 Dec 2024
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, University of Pisa, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, Universita di Cagliari - University Hospital of Cagliari, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Careggi University Hospital of Florence - Clinical Oncology Unit, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, KU Leuven, University of Pisa, affiliation not provided to SSRN, University of Florida, Università Campus Bio-Medico di Roma, Mayo Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), affiliation not provided to SSRN, AUSL Romagna - Oncology Unit, Boston Consulting Group - Berlin, University of Foggia, Fondazione IRCCS Istituto Nazionale dei Tumori, CHA University - CHA Bundang Medical Center, University of Glasgow - Institute of Cancer Sciences, University of Glasgow, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ulsan - Department of Oncology, Polytechnic University of Marche, affiliation not provided to SSRN, Universita di Cagliari - University Hospital of Cagliari, Medical University of Vienna, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ulm University - Ulm University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, San Luigi Gonzaga University Hospital, The Chinese University of Hong Kong (CUHK) - Department of Clinical Oncology, affiliation not provided to SSRN, IRCCS Humanitas Research Hospital, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, Hospital de Santa Maria, affiliation not provided to SSRN, University of Padua, Humanitas University, affiliation not provided to SSRN, AOU Careggi, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, National Cancer Center Hospital East, KU Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, Campus Bio-Medico University, Seoul National University - Seoul National University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Foggia, affiliation not provided to SSRN, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, University of Pisa, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Vita Salute San Raffaele University, IRCCS Humanitas Research Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 51 (1,052,702)

Abstract:

Loading...

Biliary Tract Cancer, gut micobiome, antibiotic therapy, Immune checkpoint inhibitors

8.

Nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma: the IKF-t006/IMMUNIB translational phase-2 study  NCT03841201

Number of pages: 27 Posted: 05 May 2026
Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Technische Universität München (TUM) - Institute of Molecular Oncology and Functional Genomics, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ludwig Maximilian University of Munich (LMU), affiliation not provided to SSRN, affiliation not provided to SSRN and Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology
Downloads 30 (1,318,317)

Abstract:

Loading...

advanced hepatocellular carcinoma, combination therapy, nivolumab, lenvatinib, 1st line

9.

Cisplatin and 5-Fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase 3 AIO/EORTC Trial (Power)

Number of pages: 31 Posted: 17 Apr 2019
Johannes Gutenberg University Mainz - I. Med. Klinik und Poliklinik, Johannes Gutenberg University Mainz - I. Med. Klinik und Poliklinik, Charité - Universitätsmedizin Berlin, Tel Aviv University - Sackler Faculty of Medicine, University of Duisburg-Essen - University Hospital Essen, University Hospital Ulm, University of Mannheim, Krankenhaus Nordwest General Hospital - Institute of Clinical Cancer Research (ICCR), Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Onkologie Leer-Emden-Papenburg, Caritas Klinikum, University of Leipzig - Faculty of Medicine, Autonomous University of Barcelona - Institute of Oncology (VHIO), University of Rostock - University Medicine Rostock (UMR), Paracelsus Medical University Salzburg, Medical University of Innsbruck, Johannes Gutenberg University Mainz, Technische Universität München (TUM) - Institute of Pathology, KU Leuven and Technische Universität München (TUM)
Downloads 30 (1,318,317)
Citation 2

Abstract:

Loading...

esophageal squamous cell cancer, panitumumab, EGFR, palliative chemotherapy, cisplatin, 5-fluorouracil